Berberine vs Ipamorelin
Moderate Research vs Well Studied
synergistic Mechanism-based · 51% Berberine helps counteract the insulin-disrupting effects of Ipamorelin. A smart combination — the insulin sensitizer mitigates metabolic side effects.
Molecular Data
Berberine Ipamorelin
Weight 336.36 Da 711.85 Da
Half-life ~4 hours ~2 hours
Chain — 5 amino acids
Type Isoquinoline alkaloid (C20H18NO4+) Growth hormone secretagogue
Key Benefits
Berberine
01 Activation of AMPK, improving cellular energy metabolism and glucose utilization
02 Clinically demonstrated reductions in fasting blood glucose and HbA1c comparable to metformin in some trials
03 Improved lipid profiles with reductions in total cholesterol, LDL cholesterol, and triglycerides
04 Enhanced insulin sensitivity through upregulation of insulin receptor expression
05 PCSK9 inhibition leading to improved LDL cholesterol clearance
06 Gut microbiome modulation favoring beneficial short-chain fatty acid-producing bacteria
07 Anti-inflammatory effects via NF-kB pathway suppression
08 Available over the counter as a dietary supplement without prescription
Ipamorelin
01 Optimal GH stimulation with superior bioavailability
02 Body composition improvements (lean mass, fat loss)
03 Enhanced recovery and anti-aging effects
04 Minimal side effects compared to other GHRPs
05 No significant cortisol or prolactin elevation
06 Improved sleep quality
Dosing Protocols
Berberine
500 mg 2-3x/day / 2-3x daily with meals
Ipamorelin
200-300 mcg per injection / 1-3 times daily depending on goals (1x for longevity, 2-3x for performance)
General Health & Longevity 200mcg 1x daily before bed
Body Composition 250-300mcg 2x daily (morning, pre-workout)
Athletic Performance 200-250mcg 2-3x daily
Sleep & Recovery 200mcg 1x daily 30min before bed
Anti-Aging Protocol 200-250mcg 1-2x daily
Side Effects
Berberine
Gastrointestinal distress (diarrhea, cramping, bloating, nausea, flatulence) - most frequent complaint, affecting 10-15% of users, especially at higher doses or without food
Constipation (less common than diarrhea but reported by some users)
Decreased appetite
Mild abdominal discomfort, particularly during the first 1-2 weeks of use
Ipamorelin
Mild hunger increase 20-30 minutes post-injection
Slight drowsiness when taken before bed
Water retention (mild)
Contraindications
Pregnancy and breastfeeding (berberine may stimulate uterine contractions and crosses into breast milk)
Neonates and young children (risk of kernicterus - berberine can displace bilirubin from albumin)
Severe hepatic impairment
Concurrent use with medications that have narrow therapeutic indices metabolized by CYP3A4 (e.g., cyclosporine, tacrolimus) without close medical supervision
Known hypersensitivity to berberine or berberine-containing plants
Pregnancy or breastfeeding
Active cancer or history of cancer
Severe kidney or liver disease
Research Evidence
Berberine Ipamorelin
Status Moderate Research Well Studied
References 5 studies 5 studies
Latest 2023 October 2024
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.